Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Modified Dantien Salee Yoga Training Program in Chronic Obstructive Pulmonary Disease Rehabilitation
COPD patients will be recruited and assigned into one of each group: 1) Control group or 2) Yoga group. In Yoga groups, subjected will be asked to participate in Modified Dantien Yoga training for 12 weeks (3 times/week, 60 min/time). The subjects will be evaluated their pulmonary function, functional fitness performance, dyspnea score, and quality of life at baseline and after 12 wk training.
| Status | Recruiting |
| Enrollment | 12 |
| Est. completion date | October 30, 2019 |
| Est. primary completion date | October 30, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 50 Years to 80 Years |
| Eligibility |
Inclusion Criteria: 1. Stable COPD patients > or equal 6 weeks. 2. Age > or equal 50-80 years. 3. FEV1 > or equal 30% predicted after take bronchodilators drug. 4. Resting SpO2 > or equal 90% room air. 5. Did not pulmonary rehabilitation program before start the yoga Exclusion Criteria: 1. Subjects with musculoskeletal disorders, mental and neurological disorders, and acute coronary heart disease. 2. Blood Pressure (systolic) > 180 mmHg. |
| Country | Name | City | State |
|---|---|---|---|
| Thailand | Faculty of Medicine, Siriraj Hospital | Bangkoknoi | Bangkok |
| Lead Sponsor | Collaborator |
|---|---|
| Mahidol University |
Thailand,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from baseline FVC (Forced Vital Capacity) (L) at 12 weeks | Change of FVC (Forced Vital Capacity) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline FEV1 (Forced Expiratory Volume in 1 minute)(L) at 12 weeks | Change of Forced Expiratory Volume in 1 second will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline TLC (Total Lung Capacity) (L) at 12 weeks | Change of TLC (Total Lung Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline FRC (Functional Residual Capacity) (L) at 12 weeks | Change of FRC (Functional Residual Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline IC (Inspiratoy Capacity) (L) at 12 weeks | Change of IC (Inspiratoy Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline RV (Residual Volume) (L) at 12 weeks | Change of RV (Residual Volume) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline MVV (Maximum Voluntary Ventilation) (L/min) at 12 weeks | Change of MVV (Maximum Voluntary Ventilation) (L/min) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline PEFR (Peak Expiratory Flow Rate) (L/sec) at 12 weeks | Change of MVV (Maximum Voluntary Ventilation) (L/sec) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline DLCO (Diffusion capacity to carbon monoxide) (ml/mmHg/min) at 12 weeks | Change of DLCO (Diffusion capacity to carbon monoxide) (ml/mmHg/min) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline PI max (Maximal Inspiratoy Pressure) (cm H2O) at 12 weeks | Change of PI max (Maximal Inspiratoy Pressure) (cm H2O) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline PE max (Maximal Expiratoy Pressure) (cm H2O) at 12 weeks | Change of PE max (Maximal Expiratoy Pressure) (cm H2O) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline FEV1/FVC % predicted at 12 weeks | Change of FEV1/FVC % Predicted (Percent Predicted of ratio of FEV1 and FVC) (% predicted) will be measured on a computerized Spirometer at the baseline and 12 weeks. | 12 weeks | |
| Primary | Change from baseline lower body strength assessed with Chair Standing test at 12 weeks | Change from baseline lower body strength assessed with Chair standing test. ( time/30 sec) | 12 weeks | |
| Primary | Change from baseline upper body strength assessed with Arm curl test at 12 weeks | Change from baseline upper body strength assessed with Arm curl test (time/30 sec) | 12 weeks | |
| Primary | Change from baseline lower body flexibility assessed with Chair Sit and Reach test at 12 weeks | Change from baseline lower body flexibility assessed with Chair Sit and Reach test (cm) | 12 weeks | |
| Primary | Change from baseline upper body flexibility assessed with Back Scratch test at 12 weeks | Change from baseline upper body flexibility assessed with Back Scratch test (cm) | 12 weeks. | |
| Primary | Change from baseline agility/dynamic balance assessed with 8-foot Up and Go test at 12 weeks | Change from baseline agility/dynamic balance assessed with 8-foot Up and Go test (sec) | 12 weeks | |
| Primary | Change from baseline Exercise Capacity assessed with 6-minute walk test at 12 weeks | Change from baseline Exercise Capacity assessed with 6-minute walk test (meter) | 12 weeks | |
| Secondary | Change from baseline Dyspnea score assessed with visual analog scale at 12 weeks | Dyspnea or shortness of breath will be measured by visual analog scale (VAS) 1-10 point scale at the baseline and 12 weeks. | 12 weeks | |
| Secondary | Change from baseline Quality of life score assessed with St. George's respiratory Questionnaires (SGRQ) at 12 weeks. | Change from baseline Quality of Life score assessed with St. George's respiratory Questionnaires (SGRQ) in Thai version at 12 weeks. | 12 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|